Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2023/24
EQL Pharma AB (publ) will publish its year-end report for the fourth quarter, 2023/24, on Tuesday, May 14[th], after stock markets closing.
EQL Pharma AB (publ) will publish its year-end report for the fourth quarter, 2023/24, on Tuesday, May 14[th], after stock markets closing.
EQL's key product Mellozzan[®] has now been launched in Germany and Austria, where it is provided to patients by EQL's license partner Medice Arzneimittel Pütter GmbH & Co. KG. In addition to Germa...
EQL's key product Mellozzan[®] has now gained marketing approval by the Health Authorities in the UK, where it is to be provided to patients by EQL's license partner Medice Arzneimittel Pütter GmbH...